In a revealing development, internal records have emerged showing that top officials from the Environmental Protection Agency (EPA) held a significant meeting with Bayer CEO Bill Anderson last year to discuss ongoing litigation linked to the company’s controversial glyphosate weed killer. This meeting, which took place on 17 June, occurred just months before the Trump administration took decisive steps to bolster Bayer’s position in a Supreme Court case that centres on claims alleging the herbicide causes cancer.
High-Level Corporate Engagement
The gathering involved key EPA figures, including Lee Zeldin, the agency’s administrator, and Nancy Beck, the principal deputy assistant administrator in the Office of Chemical Safety and Pollution Prevention. The agenda reportedly focused on litigation and ‘supreme court action’ regarding glyphosate, a herbicide widely used in products like Roundup. Bayer is currently embroiled in costly legal battles, facing accusations from thousands of individuals claiming a direct link between their cancer diagnoses and the use of glyphosate-based products.
Bayer’s strategy hinges on persuading the Supreme Court that if the EPA does not mandate a cancer warning on glyphosate products, the company should not be held legally responsible for failing to provide one. While some courts have sided with Bayer, others have dismissed this argument, a stance echoed by the Biden administration’s solicitor general.
Administration Support Following the Meeting
Since the June meeting, the Trump administration has increasingly aligned itself with Bayer. A filing on 1 December by Trump-appointed solicitor general D. John Sauer urged the Supreme Court to hear Bayer’s case, which the court subsequently accepted, scheduling a hearing for 27 April. Additionally, on 18 February, the White House invoked the Defense Production Act to safeguard the production of glyphosate, effectively granting immunity to manufacturers like Bayer.
Bayer defends its meeting with the EPA as a standard part of the regulatory process, asserting transparency regarding its litigation stance. However, critics have voiced concerns over the implications of such high-level discussions between corporate leaders and government officials. Nathan Donley from the Center for Biological Diversity highlighted the troubling trend of political appointees prioritising corporate interests over public health.
Public Health Concerns and Corporate Influence
The implications of this meeting extend beyond legal strategies; they raise significant questions about the influence of corporate lobbying on regulatory agencies. Legal experts and advocacy groups have voiced alarm over the preferential access that large companies like Bayer have to government officials compared to ordinary citizens affected by the products in question. Whitney Di Bona, a consumer safety advocate, lamented the lack of opportunity for the thousands of individuals who claim to have suffered due to glyphosate to voice their concerns directly to the EPA.
Naomi Oreskes, a Harvard professor specialising in corporate influence, remarked on the troubling pattern of industry leaders having unfettered access to decision-makers, a stark contrast to the barriers faced by the public. Zen Honeycutt, founder of Moms Across America, echoed these sentiments, emphasising that the coercive tactics employed by chemical companies to sway regulatory agencies have become all too familiar.
Why it Matters
This situation underscores the profound impact of corporate lobbying on public health policy and regulatory practices in the United States. As Bayer navigates a labyrinth of litigation while simultaneously receiving support from the highest levels of government, the potential consequences for consumer safety and environmental health are alarming. The meetings and subsequent actions reflect a concerning trend where corporate interests may overshadow the voices of those directly affected by the products they manufacture, raising critical questions about accountability and the integrity of regulatory processes in safeguarding public health.
